NYSE ARCA | ETF
Top 14 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| MNMD | Mind Medicine Inc | Healthcare | Biotechnology | 16.36% |
| CYBN | Cybin Inc | Healthcare | Biotechnology | 9.04% |
| CMPS | Compass Pathways Plc | Healthcare | Medical Care Facilities | 7.22% |
| ATAI | ATAI Life Sciences BV | Healthcare | Biotechnology | 5.66% |
| GHRS | GH Research PLC | Healthcare | Biotechnology | 5.18% |
| ITCI | Intracellular Th | Healthcare | Drug Manufacturers - Specialty & Generic | 5.11% |
| ALKS | Alkermes Plc | Healthcare | Drug Manufacturers - Specialty & Generic | 4.64% |
| RLMD | Relmada Therapeutics Inc | Healthcare | Biotechnology | 4% |
| NRXP | NRX Pharmaceuticals Inc | Healthcare | Biotechnology | 3.93% |
| SLZA | ENVERIC BIOSCI.INC.DL-01 | Healthcare | Biotechnology | 3.8% |
| SAGE | Sage Therapeutic | Healthcare | Biotechnology | 3.09% |
| NUMI | Numinus Wellness Inc | Healthcare | Medical Care Facilities | 2.08% |
| GBNH | Greenbrook TMS Inc | Healthcare | Medical Care Facilities | 1.63% |
| PSYB | PSYBIO THERAP. (SUB.VT.) | 0.26% |
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.